tetano
Editor, Senior Moderator
ACS Appl Bio Mater
. 2022 Jun 23.
doi: 10.1021/acsabm.2c00328. Online ahead of print.
Codelivery of SARS-CoV-2 Prefusion-Spike Protein with CBLB502 by a Dual-Chambered Ferritin Nanocarrier Potentiates Systemic and Mucosal Immunity
Shubing Tang[SUP] 1 [/SUP], Min Li[SUP] 1 [/SUP], Lixiang Chen[SUP] 1 [/SUP], Aguang Dai[SUP] 2 [/SUP], Zhi Liu[SUP] 2 [/SUP], Mangteng Wu[SUP] 2 [/SUP], Jingyi Yang[SUP] 1 [/SUP], Hongyun Hao[SUP] 1 [/SUP], Jingdan Liang[SUP] 3 [/SUP], Xiaohui Zhou[SUP] 1 [/SUP], Zhikang Qian[SUP] 1 [/SUP]
Affiliations
Abstract
Thousands of breakthrough infections are confirmed after intramuscular (i.m.) injection of the approved vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Two major factors might contribute to breakthrough infections. One is the emergence of mutant variants of SARS-CoV-2, and the other is that i.m. injection has an inefficient ability to activate mucosal immunity in the upper respiratory tract. Here, we devised a dual-chambered nanocarrier that can codeliver the adjuvant CBLB502 with prefusion-spike (pre-S) onto a ferritin nanoparticle. This vaccine enabled enhanced systemic and local mucosal immunity in the upper and lower respiratory tract. Further, codelivery of CBLB502 with pre-S induced a Th1/Th2-balanced immunoglobulin G response. Moreover, the codelivery nanoparticle showed a Th1-biased cellular immune response as the release of splenic INF-γ was significantly heightened while the level of IL-4 was elevated to a moderate extent. In general, the developed dual-chambered nanoparticle can trigger multifaceted immune responses and shows great potential for mucosal vaccine development.
Keywords: CBLB502; codelivery; dual-chambered; ferritin nanocarrier; prefusion-spike; systemic and mucosal immunity.
. 2022 Jun 23.
doi: 10.1021/acsabm.2c00328. Online ahead of print.
Codelivery of SARS-CoV-2 Prefusion-Spike Protein with CBLB502 by a Dual-Chambered Ferritin Nanocarrier Potentiates Systemic and Mucosal Immunity
Shubing Tang[SUP] 1 [/SUP], Min Li[SUP] 1 [/SUP], Lixiang Chen[SUP] 1 [/SUP], Aguang Dai[SUP] 2 [/SUP], Zhi Liu[SUP] 2 [/SUP], Mangteng Wu[SUP] 2 [/SUP], Jingyi Yang[SUP] 1 [/SUP], Hongyun Hao[SUP] 1 [/SUP], Jingdan Liang[SUP] 3 [/SUP], Xiaohui Zhou[SUP] 1 [/SUP], Zhikang Qian[SUP] 1 [/SUP]
Affiliations
- PMID: 35737819
- DOI: 10.1021/acsabm.2c00328
Abstract
Thousands of breakthrough infections are confirmed after intramuscular (i.m.) injection of the approved vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Two major factors might contribute to breakthrough infections. One is the emergence of mutant variants of SARS-CoV-2, and the other is that i.m. injection has an inefficient ability to activate mucosal immunity in the upper respiratory tract. Here, we devised a dual-chambered nanocarrier that can codeliver the adjuvant CBLB502 with prefusion-spike (pre-S) onto a ferritin nanoparticle. This vaccine enabled enhanced systemic and local mucosal immunity in the upper and lower respiratory tract. Further, codelivery of CBLB502 with pre-S induced a Th1/Th2-balanced immunoglobulin G response. Moreover, the codelivery nanoparticle showed a Th1-biased cellular immune response as the release of splenic INF-γ was significantly heightened while the level of IL-4 was elevated to a moderate extent. In general, the developed dual-chambered nanoparticle can trigger multifaceted immune responses and shows great potential for mucosal vaccine development.
Keywords: CBLB502; codelivery; dual-chambered; ferritin nanocarrier; prefusion-spike; systemic and mucosal immunity.